Pharmacokinetics of Zelquistinel in Fasted or Fed State

Inclusion Criteria: * Available for the entire study period; willing and able to comply with the protocol requirements and study restrictions, to remain at the CRU for the required duration of the study, and to return for the Follow-Up Visit * Male or female participants ≥18 to ≤59 years of age at Screening * Minimum body weight of at least 50.0 kg at Screening * Body mass index (BMI) 18.0 to 35.0 kg/m2, inclusive, at Screening * Able and willing to swallow whole tablets without breaking, cutting, or chewing * Non- or ex-smokers * Considered generally healthy in the opinion of an investigator upon completion of medical history, physical examination, vital sign measurements, Screening clinical laboratory test results, and Screening ECG * Female participants of childbearing potential must use an acceptable method of contraception, including hormonal contraceptives, abstinence from heterosexual intercourse, intrauterine device with or without hormones, or double-barrier method (eg, condom and spermicide) for 30 days before Screening, during the study, and for 30 days after the last administration of study drug * Female participants of nonchildbearing potential should be surgically sterile (ie, have undergone complete hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses) * Male participants must agree to use a double-barrier method (condom and spermicide) or remain abstinent from hete…